Enterprise Value
-84.86M
Cash
110.2M
Avg Qtr Burn
-6.708M
Short % of Float
8.26%
Insider Ownership
5.74%
Institutional Own.
25.39%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II | Phase 3 Data readout | |
Phase 2 Update | ||
Phase 2 Update | ||
AVTX-009 Details Hidradenitis suppurativa, Autoimmune disease | Phase 2 Initiation | |
Quisovalimab/ AVTX-002 (CERC-002) Details Crohns disease | Phase 1b Update | |
AVTX-007 (CERC-007) Details Multiple myeloma, Adult Onset Still's Disease | Phase 1b Update | |
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-006 (CERC-006) Details Lymphatic malformations | Failed Discontinued |